America currently has a heroin problem. Can private sector innovations help?
America currently has a heroin problem, and those of us on the front lines have seen it firsthand. It is glaring at us with a doubling of the population using heroin, as well as an increase in hospital admissions for complications resulting from substance abuse.1,2 With the Institute of Medicine’s (now the National Academy of Medicine) recent publication calling for the development of evidence-based standards for mental health and substance abuse disorders, there is renewed interest in understanding how best to curb this disturbing trend.3
Beyond the individual and public health benefit, I have gained a new appreciation for the impact of substance abuse on healthcare expenditures and services. Although the government has borne the greater share of substance abuse treatment in the last few decades, limited state and local funding has necessitated a recent increase of private insurance and out-of-pocket spending for substance abuse treatment.4 Furthermore, patients with drug dependence are likely to present to the hospital with severe medical conditions2—heroin abuse in particular leads to skin, respiratory, and cardiac conditions that require costlier and longer hospital stays.
While some benefit managers may view this increase in substance abuse treatment spending as another expense that must be managed, I view this as an opportunity. The prior year-to-year pattern of spending unintentionally favored treating substance abuse patients once they had costly complications.4 With an increased share of the spending with the private sector, there is room for innovative models that can prevent those costly complications from even happening. The suburban mother with a new broken bone and a susceptibility to addiction will be monitored more closely for her narcotic prescriptions. No longer will the asthmatic who inhales heroin present to the emergency department with chest pain and an asthma exacerbation, and he can also be remotely monitored for worsened breathing before it becomes an acute issue.
In fact, there are many start-up companies that intend to change the face of mental health and substance abuse. 1DocWay, which aims to provide telepsychiatry and in-person services to increase access to underserved communities in a cost-effective model, recently received funding from Village Capital, a venture firm, to grow their services. Additionally, Wellframe, a care management platform, has created a mental health product that allows clinicians to engage with patients and to provide a touch point at their time of need. The program Joyable provides coach-supported cognitive behavioral therapy, an evidence-based psychotherapy treatment for mood disorders, which is frequently associated with substance abuse. Ginger.io tackles the mental health issue using big data, claiming to use self-reported information to identify those who need assistance in the population. Perhaps new innovative primary care models will integrate mental health services to ensure appropriate prescription opiate drug use and encourage strong monitoring of those who are predisposed to substance abuse.
However, the demographics of patients with substance abuse are changing. In the last decade, there has been a 60% increase in the prevalence of heroin abuse among people with private insurance.1 Although substance abuse still represents a small fraction of private spending, this sector will need to take a leadership role in identifying and treating at-risk and vulnerable patients before they become dependent on public funding sources.
There is no question that we are in the midst of an innovation burst in healthcare. Let's continue to encourage the brightest minds to solve our toughest problems, including those within mental health.
1. Jones CM, Logan J, Gladden RM, Bohm MK. Vital signs: demographic and substance use trends among heroin users—United States, 2002-2013. MMWR. 2015;64(26):719-725.
2. Choi H, Krantz A, Smith J, Trick W. Medical diagnoses associated with substance dependence among inpatients at a large urban hospital. PLoS ONE. 2015;10(6):e0131324.
3. IOM. Psychosocial interventions for mental and substance use disorders. Institute of Medicine; 2015.
4. National expenditures for mental health services and substance abuse treatment, 1986-2009. Substance Abuse and Mental Health Services Administration; 2013. [HHS Publication No. SMA-13-4740.]
Exagamglogene Autotemcel Shows Promise in Treatment of Transfusion-Dependent β-Thalassemia
April 30th 2024An ongoing, phase 3, open-label study demonstrated the efficacy of exagamglogene autotemcel (exa-cel) infusion to promote transfusion dependence in patients with transfusion-dependent β-thalassemia (TDT).
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Medicaid, Medicare Policy Changes Could Lead to More Than 25,000 Additional Deaths, Study Says
April 30th 2024Researchers also estimated that more than 700,000 Americans with diabetes could lose insurance coverage if these proposed retractions are put into place, with some new policies already in effect.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Makers of medical tests will have about 4 years to show the FDA that their new offerings deliver accurate results; after previously decreasing for 27 years, US tuberculosis (TB) cases increased every year since 2020; a US district judge rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to the Medicare drug price negotiation program.
Read More